These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27177756)

  • 1. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug treatment for melanoma: progress, but who pays?
    Kefford RF
    Med J Aust; 2012 Aug; 197(4):198-9. PubMed ID: 22900855
    [No Abstract]   [Full Text] [Related]  

  • 4. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
    Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA
    Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
    Jones C; Zhao Z; Barber B; Bagijn M; Corrie P; Saltman D
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):862-6. PubMed ID: 25988349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
    Culos KA; Cuellar S
    Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
    Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
    BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
    Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
    Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
    Koprowska K; Czyż M
    Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
    Banaszynski M; Kolesar JM
    Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
    J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.